Abstracts

Effectiveness of Taiwan Nationwide HBV Vaccination in Persons at Risk for HIV Infection

Background: The prevalence of chronic hepatitis B virus (HBV) infection was estimated 15% to 20% in the adults, regardless of HIV infection, who were born before universal neonatal hepatitis B virus (HBV) vaccination program was launched in 1986. The neonatal HBV vaccination program and catch-up vaccination program have significantly reduced acute and chronic HBV infection…

Vaccine Escape Mutants and Suboptimal Hepatitis B Virus Response in HIV HBV coinfected patients

Background: Immune and antiviral-associated S gene mutations are associated with potential vaccine escape and are thus a major public health concern. The frequency of these mutations during antiretroviral therapy (ART) is unknown in ART-naive HIV hepatitis B virus (HBV) coinfected patients with suboptimal HBV response, especially in sub Saharan Africa. Methodology: 200 ART naive, HIV-infected…

HBsAg Genetic Elements Critical for Immune Escape Drive HBV Reactivation Upon Immunosuppression

Background: HBV reactivation is defined as an abrupt reappearance or rise of serum HBV DNA in patients (pts) with resolved or inactive HBV infection. The role of HBsAg genetic diversity in this phenomenon is still anecdotic. Here, we investigate HBsAg genetic signatures underlying HBV reactivation under immunosuppression. Methodology: This study included 129 HBV D Genotype…

Increased Hepatitis B Virus Coinfection Screening Following a Change in Zambian HIV Guidelines

Background: Screening all HIV-infected adults for hepatitis B virus (HBV) co-infection is recommended by the World Health Organization but is not commonly practiced in sub-Saharan Africa. In 2010, the Zambian Ministry of Health (MoH) recommended a change from targeted screening, based on clinical suspicion of liver disease, to universal HBV screening at enrollment. We describe…

Determinants of Cognitive Impairment in HIV-Positive Men on cART and Uninfected Controls

Background: HIV-positive individuals may be at increased risk of cognitive impairment (CI). The contribution of HIV-, antiretroviral treatment- and non-HIVrelated risk factors towards CI remains to be clarified further. Methodology: 103 HIV-infected men with suppressed viraemia on cART for ≥12 months and 75 uninfected male controls (comparable regarding age, ethnicity, IQ and education), all aged…

Novel Method for More Reliably Estimating the Burden of Cognitive Impairment in HIV

Background: The commonly used published Frascati criteria likely overestimate HIV-associated neurocognitive disorder (HAND) prevalence. Modified criteria proposed by Gisslen attempt to reduce sensitivity while retaining specificity. Multivariate normative comparison (MNC), specifically designed to control for false-positive rate while retaining sensitivity, is a novel and potentially more accurate technique for evaluating cognitive impairment (CI). Methodology: 103…

A Comparison of the Pharmacokinetics of Raltegravir During Pregnancy and Postpartum

Background: During pregnancy physiological changes take place which can influence the pharmacokinetics (PK) of antiretroviral agents and lead to decreased drug exposure. Effective plasma concentrations are important to prevent treatment failure, development of resistance and mother-to-child transmission. According to perinatal guidelines raltegravir (RAL) can be used in pregnant HIV infected women in special circumstances, because…